A cancer charity has said it is "angry and frustrated" that ministers and health officials have not approved the provision of ...

Future Oncol. 2010;6(5):665-679. Three Phase I studies by O'Donnell and colleagues have reported the pharmacodynamic activity of abiraterone acetate, which was originally developed as an oral ...

Cedric Pobel, MD, covers the PEACE-1 trial of radiotherapy, standard of care, and abiraterone in low-volume metastatic castration-sensitive prostate cancer.

In a live event, Ganesh V. Raj, MD, PhD, discussed the drug-drug interactions and outcomes by disease volumes across ARPI trials in mHSPC.

In the current study, we reported the efficacy and toxicity of AA in mCRPC patients from an unselected patient population in a non-trial setting. The inclusion of all AA-treated patients in all ...

Triple therapy with darolutamide vs abiraterone for metastatic hormone-sensitive prostate cancer is associated with better clinical outcomes. Triplet therapy that includes darolutamide vs ...

We transformed care for advanced prostate cancer, by validating inhibitors of androgen production as an effective cancer treatment, and discovering and developing abiraterone, a life-extending ...

Homologous recombination deficiency signature (HRDsig+) and the genomic landscape of clinically advanced prostate carcinoma (CAPC). This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary ...

Abiraterone acetate is used along with prednisolone (corticosteroid) for treating a type of prostate cancer called metastatic castration-resistant prostate cancer (mCRPC) previously called hormone ...

Osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with denosumab in a randomized phase III trial comparing 4 vs. 12 weekly administration ...